No annual revenue total was found in Biohaven Ltd.'s SEC filings.
Biohaven Ltd. (BHVN) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$610.2 million. As of Sep 30, 2026 it held $161.1 million in cash and investments and $36.1 million in total debt.
Revenue
—
Net income (TTM)
$-542.68M
+30.4% vs year-ago TTM
Operating cash flow (TTM)
$-472.53M
+27.2% vs year-ago TTM
Free cash flow (TTM)
$-473.17M
+27.2% vs year-ago TTM
EPS (TTM)
$-3.81
+49.7% vs year-ago TTM
Dividend per share
None
Shares outstanding
150.42M
+47.4% vs prior year
Net cash
$124.97M
as of Sep 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BHVN (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Virgin Islands, British
- Headquarters
- New Haven, CT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1935979
- Former names
- Biohaven Research Ltd. (until Sep 14, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Operating income | -$745.4M | -$885.1M | -$436.1M | -$567.9M |
| Net income | -$738.8M | -$846.4M | -$408.2M | -$570.3M |
| Diluted EPS | -$6.86 | -$9.28 | -$5.73 | -$12.75 |
| Operating cash flow | -$609.4M | -$582.5M | -$331.7M | -$297.7M |
| Free cash flow | -$610.2M | -$586.5M | -$334.8M | -$303.8M |
| Total assets | $451.4M | $615.1M | $513.2M | $661.8M |
| Total liabilities | $399.4M | $191.7M | $85.2M | $123.0M |
| Stockholders' equity | $52.1M | $423.4M | $428.0M | $538.8M |
| Cash and investments | $319.1M | $486.0M | $381.8M | $465.3M |
| Total debt | $45.7M | $36.6M | $30.9M | $33.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 15, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 4, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 26, 2026 | Aug 26, 2026 |
All 282 Biohaven Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.